Celeris Therapeutics

company

About

Harnessing deep learning and lab automation to accelerate drug discovery in targeted protein degradation.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
€3M
Industries
Artificial Intelligence,Biotechnology,Information Technology,Life Science,Pharmaceutical
Founded date
Jan 1, 2021
Number Of Employee
11 - 50
Operating Status
Active

Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers.

Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles.

Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€3M
Celeris Therapeutics has raised a total of €3M in funding over 2 rounds. Their latest funding was raised on Feb 10, 2022 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 10, 2022 Seed €3M 1 i&i Prague Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Celeris Therapeutics is funded by 1 investors. i&i Prague are the most recent investors.
Investor Name Lead Investor Funding Round
i&i Prague Yes Seed